The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

Myeloid Leukaemia ◽

Dose Escalation ◽

Older Patients ◽

Resistance Modulation ◽

The Impact ◽

A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome

http://isrctn.org/> ◽

10.1186/isrctn31682779 ◽

2013 ◽

Author(s):

Nigel Russell

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

National Cancer Research Institute acute myeloid leukaemia and high risk MDS trial 16. A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome (MDS).

http://isrctn.org/> ◽

10.1186/isrctn11036523 ◽

2012 ◽

Author(s):

Alan Burnett

Keyword(s):

Cancer Research ◽

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

Cancer Research Institute ◽

National Cancer Research Institute ◽

Acute Myeloid ◽

Research Institute

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high‐risk myelodysplastic syndrome

European Journal Of Haematology ◽

10.1111/ejh.13196 ◽

2019 ◽

Vol 102 (3) ◽

pp. 218-226

Author(s):

Marie Warny ◽

Jens Helby ◽

Henrik Sengeløv ◽

Børge G. Nordestgaard ◽

Henrik Birgens ◽

...

Keyword(s):

Bone Marrow ◽

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Telomere Length ◽

Mononuclear Cell ◽

Bone Marrow Mononuclear Cell ◽

Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism

The Lancet Haematology ◽

10.1016/s2352-3026(15)00200-8 ◽

2015 ◽

Vol 2 (10) ◽

pp. e396-e397 ◽

Cited By ~ 1

Author(s):

Rena Buckstein

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Cited By ~ 19

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

DUPLICATE - A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over

http://isrctn.org/> ◽

10.1186/isrctn42347148 ◽

2013 ◽

Author(s):

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Randomised Trial ◽

Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukaemia or myelodysplastic syndrome

http://isrctn.org/> ◽

10.1186/isrctn62207270 ◽

2013 ◽

Author(s):

AK Burnett

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structural abnormalities of chromosome 5

http://isrctn.org/> ◽

10.1186/isrctn58492795 ◽

2012 ◽

Author(s):

David Bowen

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Chromosome 5 ◽

Standard Chemotherapy ◽

Structural Abnormalities ◽

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age

British Journal of Haematology ◽

10.1111/bjh.13437 ◽

2015 ◽

Vol 170 (3) ◽

pp. 349-355 ◽

Cited By ~ 6

Author(s):

Sarah A. Buckley ◽

Raya Mawad ◽

Ted A. Gooley ◽

Pamela S. Becker ◽

Vicky Sandhu ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Low Dose ◽

Previously Treated ◽

Low Dose Cytarabine ◽

Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome

British Journal of Haematology ◽

10.1111/j.1365-2141.2007.06670.x ◽

2007 ◽

Vol 138 (4) ◽

pp. 555-557 ◽

Cited By ~ 4

Author(s):

Masamitsu Yanada ◽

Xuelin Huang ◽

Guillermo Garcia-Manero ◽

Susan O'Brien ◽

Farhad Ravandi ◽

...

Keyword(s):

Targeted Therapy ◽

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Initial Treatment ◽

Haematological Improvement ◽